Tenax Therapeutics (NASDAQ:TENX) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research report released on Friday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

A number of other equities research analysts have also recently weighed in on the company. William Blair reaffirmed an “outperform” rating on shares of Tenax Therapeutics in a research note on Monday, March 10th. Leerink Partners set a $20.00 target price on Tenax Therapeutics in a research report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Tenax Therapeutics Price Performance

Shares of TENX stock opened at $5.89 on Friday. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $7.89. The firm has a market cap of $24.43 million, a PE ratio of -2.38 and a beta of 1.92. The company has a 50-day moving average of $5.86 and a two-hundred day moving average of $5.92.

Tenax Therapeutics (NASDAQ:TENX) last posted its quarterly earnings data on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. Sell-side analysts anticipate that Tenax Therapeutics will post -0.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Tenax Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC purchased a new stake in shares of Tenax Therapeutics during the fourth quarter worth $1,026,000. ADAR1 Capital Management LLC boosted its holdings in Tenax Therapeutics by 98.1% in the first quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock valued at $450,000 after purchasing an additional 34,048 shares during the period. Millennium Management LLC acquired a new position in Tenax Therapeutics during the 4th quarter worth $166,000. Geode Capital Management LLC increased its holdings in Tenax Therapeutics by 32.4% during the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after purchasing an additional 5,964 shares during the period. Finally, Two Sigma Investments LP purchased a new stake in Tenax Therapeutics during the 4th quarter worth about $84,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.